These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 31160308)
1. The Achilles Heel of Malignant Rhabdoid Tumors. Huang J; Luo J Cancer Res; 2019 Jun; 79(11):2808-2809. PubMed ID: 31160308 [TBL] [Abstract][Full Text] [Related]
2. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442 [TBL] [Abstract][Full Text] [Related]
3. Pathology and diagnosis of SMARCB1-deficient tumors. Margol AS; Judkins AR Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033 [TBL] [Abstract][Full Text] [Related]
4. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Caramel J; Medjkane S; Quignon F; Delattre O Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027 [TBL] [Abstract][Full Text] [Related]
5. Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. Pinto EM; Hamideh D; Bahrami A; Orr BA; Lin T; Pounds S; Zambetti GP; Pappo AS; Gajjar A; Agnihotri S; Broniscer A Acta Neuropathol; 2018 Aug; 136(2):315-326. PubMed ID: 29428974 [TBL] [Abstract][Full Text] [Related]
6. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors. Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280 [TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress. Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298 [TBL] [Abstract][Full Text] [Related]
8. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315 [TBL] [Abstract][Full Text] [Related]
10. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis. Darr J; Klochendler A; Isaac S; Eden A Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500 [TBL] [Abstract][Full Text] [Related]
11. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Chai J; Lu X; Godfrey V; Fletcher C; Roberts CW; Van Dyke T; Weissman BE Cancer Res; 2007 Apr; 67(7):3002-9. PubMed ID: 17409406 [TBL] [Abstract][Full Text] [Related]
12. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors? Renard C; Pissaloux D; Decouvelaere AV; Bourdeaut F; Ranchère D Cancer Genet; 2014 Sep; 207(9):384-9. PubMed ID: 25053104 [TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904 [TBL] [Abstract][Full Text] [Related]
14. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917 [TBL] [Abstract][Full Text] [Related]
16. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy. Kerl K; Holsten T; Frühwald MC Pediatr Hematol Oncol; 2013 Oct; 30(7):587-604. PubMed ID: 23848359 [TBL] [Abstract][Full Text] [Related]
17. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366 [TBL] [Abstract][Full Text] [Related]
18. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Kohashi K; Oda Y; Yamamoto H; Tamiya S; Oshiro Y; Izumi T; Taguchi T; Tsuneyoshi M Am J Surg Pathol; 2008 Aug; 32(8):1168-74. PubMed ID: 18580682 [TBL] [Abstract][Full Text] [Related]
19. Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays. Takita J; Chen Y; Kato M; Ohki K; Sato Y; Ohta S; Sugita K; Nishimura R; Hoshino N; Seki M; Sanada M; Oka A; Hayashi Y; Ogawa S Cancer Sci; 2014 Mar; 105(3):258-64. PubMed ID: 24418192 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Hoot AC; Russo P; Judkins AR; Perlman EJ; Biegel JA Am J Surg Pathol; 2004 Nov; 28(11):1485-91. PubMed ID: 15489652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]